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21-32 million and 418-456 QALY gained for 25% and 80% uptake. The results were 
sensitive to the proportion of inpatient presentation at ED and utility during influ-
enza. ConClusions: Results clearly demonstrate that both 75 mg BID standard and 
150 mg BID high dose oseltamivir therapy are cost saving. The findings corroborate 
antiviral therapy as being a valuable component of pandemic influenza planning 
decisions in the US.
InfectIon – Patient-Reported outcomes & Patient Preference Studies
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Meta-analySIS of XuebIjIng joInt ulInaStatIn tReatIng SePSIS
Liu G.1, Li Q.2
1Guanghua School of Management, Peking University, Beijing, China, 2China Pharmaceutical 
University, Nanjing, China
objeCtives: To compare the efficacy of Xuebijing injection and ulinastatin injec-
tion for the treatment of inflammation and sepsis by evaluating plasma tumor 
necrosis factor (TNF-α ), interleukin IL-6, procalcitonin (PCT), the average length of 
stay and the average duration of mechanical ventilation. Methods: Literatures 
from January 2004 to August 2013 were retrieved from the online databases such 
as CNKI, CQVIP and Wanfang Data. The documents and data, selected according to 
the inclusion and exclusion criteria, were analyzed by RevMan5.0 Meta-analysis 
software. Results: Four randomized controlled clinical trials were included, 
with 181 patients in the experimental group (Xuebijing +Ulinastatin +based treat-
ment) and 181 patients in the control group (Ulinastatin + basic treatment). Meta-
analysis showed that the tumor necrosis factor TNF-a levels [WMD = -5.16,95% CI 
(-11.07,0.76)] of experimental group and the control group were not statistically 
different, but the interleukin IL-6 levels[WMD= -57.82,95%CI (-112.12, -3.52)] , the 
procalcitonin PCT [WMD= -0.53,95%CI (-0.88, -0.19)] levels , the average length of 
stay [WMD = -3.63,95 % CI (-4.68, -2.58)] and the average duration of mechanical 
ventilation [WMD = -3.77,95% CI (-4.70, -2.83)] of the experimental group and the 
control group were statistically different. ConClusions: Current results indicated 
that the application of Xuebijing injection for the treatment of sepsis provided a 
lower level of interleukin IL-6 and procalcitonin PCT, a shorter length of stay and 
duration of mechanical ventilation.
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effect of HealtH educatIon PRogRaM on Knowledge, attItude, 
PRactIce and HealtH Related QualIty of lIfe In HePatItIS-b PatIentS
Haq N.1, Hassali M.A.2, Shafie A.A.2, Saleem F.2, Farooqui M.3, Iqbal Q.1
1University of Balochistan, Quetta, Pakistan, 2Universiti Sains Malaysia, Penang, Malaysia, 
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objeCtives: This study was conducted to evaluate the effect of a pharmacist ini-
tiated health education programme for improving Hepatitis-B patients’ disease 
state knowledge, attitude, practice and health related quality of life in Quetta city, 
Pakistan. Methods: The study was conducted as non-clinical randomization control 
trial. It was divided into four phases: pre-interventional assessment, training of hospi-
tal pharmacists, development and implementation of the intervention program and 
post-interventional analysis. The pre-interventional phase analysed the Hepatitis-B 
(HB) patients’ knowledge, attitude and practice and current status of Health Related 
Quality of Life (HRQoL). Results: Three hundred and ninety HB patients were tar-
geted for the study. The pre-interventional analysis revealed poor knowledge (mean 
score 8.48 ±2.7 out of 20), negative attitude (mean scores 3.87±1.2 out of 7) and bad 
practice (mean scores 2.37±1.0 out of 8). The HB patients also had poor Health Related 
Quality of Life (mean score of 37.22±30.0 out of 100). The post-interventional data were 
available from 126 patients of interventional group and 151 patients of control group, 
giving a response rate of 64.6% and 77.4% respectively. No significant association was 
observed among demographics variables. However, knowledge, attitude and practice, 
and HRQoL scores were significantly associated (p< 0.001) when compared between 
interventional and control group after the completion of the intervention. There was 
an increase in mean knowledge score (15.46±2.2), attitude score (5.05±1.1), practice 
(5.98±1.1) Health Related Quality of Life (48.16±25.2). The inter-group difference among 
pre- and post- interventional groups reported a significant difference (p< 0.001) when 
knowledge, attitude and practice and HRQoL were compared. ConClusions: The 
educational intervention significantly increase in the HB patients’ knowledge, attitude 
and practice, and HRQoL. Therefore, the role of pharmacists in patient education 
must be formalized and acknowledged as an official part of the health care system.
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aSSeSSMent of QualIty of lIfe In HuMan IMMunodefIecIency VIRuS 
PoSItIVe PatIentS wItH adVeRSe ReactIonS to antIRetRoVIRal tHeRaPy 
In teRtIaRy caRe HoSPItal
Aluri R.K.C.
Manipal University, MANIPAL, India
objeCtives: The main aims of the study was to estimate the health related qual-
ity of life(HRQOL) between Adverse drug reaction (ADR) and Non ADR retroviral 
patients who are on anti retroviral therapy. Methods: A prospective spontaneous 
, reporting study was conducted over a period of 6 months by clinical pharmacist. 
Each reported ADR was assessed for its causality and severity by using Naranjo ‘s 
scale and Hartwig et al scale .The management of reported ADRs and the treatment 
given for ADR are determined. Health related quality of life is assessed by giving a 
35 item MOS- HIV Questionnare to each individual retroviral patients who are on 
Highly active antiretroviral therapy (HAART) for atleast 45 days by calculating the 
HRQOL score. Results: A Total of 46 ADRs (N= 100) were identified out of which 
30 are males and 16 are females. The assessment by Naranjos scale showed that 
out of 46 ADRs, 8 ADRs were probable, 35 ADRs were possible and 3 ADRs were 
unlikely. Severity assessment by hartwig et al scale showed that 32 ADRs come 
under mild level, 14 ADRs come under moderate level and none come under severe 
level.The Health related quality of life between ADR patients and Non ADR absent 
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How can a MultIleVel PRoMotIon of bReaStfeedIng Reduce tHe 
ReQuIRed budget foR RotaVIRuS VaccInatIon In IndoneSIa?
Zakiyah N., Suwantika A.A., Postma M.J.
University of Groningen, Groningen, The Netherlands
objeCtives: Breast milk is considered to give protection against rotavirus infection 
since it contains anti-rotavirus maternal antibodies and other nonspecific inhibi-
tors. Multilevel promotion of breastfeeding is a complex intervention that modifies 
behavioral determinants through multiple levels of health promotion. This interven-
tion can prolong the duration and increase the prevalence of exclusive breastfeed-
ing. This study aims to investigate the effect of multilevel promotion of breastfeeding 
on reducing the required budget for rotavirus vaccination in Indonesia. Methods: 
We developed an age-structured cohort model within a 5-year-time-horizon for the 
2013 Indonesia birth cohort. We compared two situations: (i) baseline, reflecting 
the current situation for the population of under-5-years-old, and (ii) the current 
situation with an additional multilevel promotion of breastfeeding. We used Monte 
Carlo simulations to examine the economic acceptability and affordability of the 
rotavirus vaccination. Results: Vaccination coupled with multilevel promotion 
of breastfeeding could reduce rotavirus-diarrhea by 493,235 cases. At a vaccine 
price of US$ 5.0 per dose, multilevel promotion of breastfeeding could reduce the 
required budget for the implementation of three-dose rotavirus vaccination by US$ 
50,000, compared to the current absence of specific promotion. ConClusions: 
Multilevel promotion of breastfeeding could potentially reduce the required budget 
for rotavirus vaccination. Mortality rate and vaccine price were the most influential 
parameters on the sensitivity analyses.
PIn26
coSt-utIlIty analySIS of 10- and 13-Valent PneuMocococcal 
conjugate VaccIneS In tHe PHIlIPPIneS
Haasis M.A., Ceria J.A.
Department of Health, Manila, Philippines
objeCtives: The objective of this study is to evaluate the costs-effectiveness of 
introducing pneumococcal conjugate vaccine as part of the childhood immuniza-
tion program in the Philippines. Methods: A cost-utility analysis was conducted 
using a lifetime horizon. A Markov simulation model was used to examine the 
comparative cost-effectiveness of PCV10 and PCV13 against the current scenario 
of no vaccination. A health system perspective was employed to explore different 
funding schemes, which include full or partial vaccination coverage subsidized by 
the government and self-paid vaccination in the private sector. An annual discount 
rate of 3.5% for future costs and outcomes was applied. Results were presented as 
incremental cost-effectiveness ratios (ICERs) per QALY gained. Sensitivity analysis 
was performed to determine the impact of parameter uncertainty. Results: With 
universal vaccination by the government at a cost per dose of Php 624 for PCV10 and 
Php700 for PCV13, the ICER for PCV10 and PCV13 were Php 68,086 and Php 67,631 
per QALY gained, respectively, compared to no vaccination. Partial vaccination of 
25% and 50% of the birth cohort yielded considerably higher ICER values that are 
still below the country ceiling threshold of Php 170,000 per QALY gained, because of 
the loss of herd protection. The analysis also found that with a partial vaccination 
strategy of the government, having at least 10% of the target cohort self-pay a higher 
market price of Php 2.056 for PCV10 and Php 3,545 for PCV13 would make vaccina-
tion cost-ineffective, because of the high out-of-pocket costs. ConClusions: The 
inclusion of PCV in the national immunization program with either universal or 
partial coverage would be a cost-effective intervention in the Philippines compared 
to no vaccination. However, the affordability and sustainability of PCV implementa-
tion over the long term should be considered by decision makers.
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coSt-utIlIty analySIS of oPtIMal doSIng of oSeltaMIVIR undeR 
PandeMIc Influenza uSIng a noVel aPPRoacH: lInKIng HealtH 
econoMIcS and tRanSMISSIon dynaMIc ModelS
Wu D.B.C.1, Chaiyakunapruk N.1, Pratoomsoot C.2, Lee K.K.C.3, Chong H.Y.1, Nelson R.E.4, Smith 
P.F.5, Kirkpatrick C.6, Kamal M.A.7, Nieforth K.5, Dall G.5,  Toovey S.8, Kong D.C.6, Kamauu A.9, 
Rayner C.5
1Monash University Malaysia, Selangor, Malaysia, 2Naresuan University, Muang, Thailand, 
3Monash University, Kuala Lumpur, Malaysia, 4University of Utah, Salt Lake City, UT, USA, 5d3 
Medicine Limited, Parsippany, NJ, USA, 6Monash University, Parkville, Australia, 7Hoffmann La-
Roche, New York, NY, USA, 8Pegasus Research, Basel, Switzerland, 9Anolinx, LLC, Salt Lake City, 
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objeCtives: Some recent pharmacological evaluations support that higher expo-
sures of oseltamivir may further reduce duration of influenza viral shedding and 
symptoms. This study investigated the economic impact of oseltamivir standard 
(75 mg BID) and high (150 mg BID) dose treatment and its potential in supporting 
pandemic influenza planning decisions in the US. Methods: A health economic 
(HE) decision analytic model was linked to a pharmacokinetic/pharmacodynamics 
(PK/PD) - transmission dynamic model which simulated the infected population 
in an influenza outbreak under different scenarios. A cost-utility analysis, under 
the US societal perspective, was conducted; comparing oseltamivir 150mg versus 
approved 75mg BID, and no treatment, three levels of uptake (25%, 50%, and 80%), for 
a strain with comparable virulence to typical seasonal-influenza. Model parameters 
such as probabilities, costs (2013 USD), lengths of stay, and utilities were derived 
from published studies. In the HE model, an infected patient was either treated 
with oseltamivir in the outpatient setting or admitted into the hospital, leading 
to no complications, pneumonia, sepsis, and acute respiratory distress syndrome. 
Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratios (ICERs) were determined over one-year time horizon. Sensitivity analyses 
were undertaken. Results: Under low virulence and low transmissibility scenarios, 
in comparison with no treatment, the use of 75mg BID oseltamivir showed cost-
saving of USD 31-33 million million and 395-452 QALY gained for 25% and 80% 
uptake, respectively. Compared to no treatment, oseltamivir 150 mg BID saved USD 
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drugs indicated for influenza (24%) and viral infections (excluding HIV and hepa-
titis) (18%). ConClusions: From the analysis presented here, it is clear that there 
are striking differences between infectious and parasitic disease drug approvals in 
Japan and the USA. Given the concern in Japan over the emergence of new influenza 
strains with pandemic potential, this is a great focus, constituting approximately 
a quarter of all infectious and parasitic disease drugs for the PMDA compared to 
no submissions to the FDA.
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PoPulatIon acceSS to RotaVIRuS VaccInatIon In InduStRIalIzed 
countRIeS: leSSonS leaRnt fRoM cuRRent eXPeRIence
Toumi M.1, Aballea S.2, Millier A.2
1University of Marseille, Marseille, France, 2Creativ-Ceutical, Paris, France
objeCtives: In most European countries, there are usually four steps before popu-
lation access to a vaccination programme: vaccine marketing authorization by the 
European Commission, transposition of this agreement by national drug agencies, 
then recommendation and policy-decision steps on funding and implementation. 
During the recommendation step, specific to vaccines, health technology assess-
ment is often performed. Using rotavirus vaccination as an illustrative case, this 
study aims at better understanding the picture of population access, and identifying 
lessons learnt from current experience. Methods: An extensive systematic review 
of national universal rotavirus vaccination policies was conducted in 20 industrial-
ized countries (17 European & 3 major non-European). After key categories in vac-
cine evaluations were identified, comparative quantitative and qualitative analyses 
were conducted. Results: At mid-March 2014, out of the 20 countries considered, 13 
decided to include rotavirus vaccination in their childhood national vaccination pro-
gramme, 2 decided not to include it, while rotavirus decision-making process has not 
started or is underway in the remaining five countries. Published evaluations and/or 
advices on rotavirus vaccination were available in 16 countries. Quantitative analyses 
revealed that most of the countries did not take all categories into consideration, and 
some countries even assessed only two or three. ‘Burden of disease’ and ‘assessment 
of vaccine efficacy/safety’ were always taken into account, while ‘acceptability’ and 
‘implementation’ were less addressed. Qualitative analyses pointed out many differ-
ences in content and outcomes. ConClusions: Rotavirus vaccination policies across 
industrialised countries were found to be disparate, leading to unequal population 
access. Comparative analyses suggest there are different interpretations of the avail-
able evidence. This raises the need of a common decision integrated framework, using 
structured and systematic approach. This approach is not intended to substitute to 
authorities, but it could contribute to provide reproducible and structured interpreta-
tion of evidence, pave the way of the legitimacy of rotavirus vaccination programme.
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SPendIng on HIV and aIdS In IndoneSIa: tHe Role of goVeRnMent and 
otHeR PublIc SouRce of fund to MaIntaIn QualIty and eQuIty
Hadiyin Rifai M.N.
Universitas Indonesia, faculty of Public Health, Depok, Indonesia
objeCtives: This study is aiming at 1) tracking expenditure on HIVAIDS, 2)how 
the government contributed to one of the MDG priority programs in Indonesia 
and its sustainability for future financing since Indonesia is one country with 
growring number of new HIVAIDS infections. Methods: Cross sectional data from 
2006-2012 was used to capture spending for HIVAIDS interventions, followed by 
policy discussion. Results: Total spending for HIVAIDS interventions increased 
from USD 56,5 miilion in 2006 to USD 87 million in 2012. The government contri-
bution has slightly increased (26.6% in 2006 and 42.36% in 2012). We found that 
75% in 2011 and 70% in 2012 of the spending were related to health. Government 
contribution for HIVAIDS as compared to total health expenditure was very lim-
ited, amounted to 0,29%, 0,27% and 0,26% in 2009, 2010 and 2011 respectively. In 
contrast, for priority programs such as HIVAIDS, external partner contribution 
has been substantial. There has been a discussion to integrate financing to the 
publicly funded program such as universal coverage that has just started recently. 
Further analysis on Opportunitistic Infection and STDs service provision for most 
at risk population was done to assess potential inclusion to the benefit package. 
Separation of the cost components to balance the role of the government and 
other sources was also assessed. Unit cost of the STDs treatment is USD 24 exclud-
ing equipment and drug. However,other country’s experience showing that the 
interventions are integrated in the universal coverage using different scheme or 
top-up. ConClusions: It should be carefully assessed the integration of HIVAIDS 
treatment to the universal coverage scheme. Stigma reduction and different price 
for private clinics need to be explored to support quality and equity. To ensure 
sustainability of the program government should play a central role to maintain 
the program, involving NGOs to engage MARP and PLHIV.
neuRologIcal dISoRdeRS – clinical outcomes Studies
Pnd1
IVacaftoR foR PatIentS wItH cyStIc fIbRoSIS: clInIcal effIcacy and 
coSt-effectIVeneSS
Kostyuk A.1, Nurgozhin T.2, Akanov A.3
1Almaty State Instiitute for Continuing Medical Education, Astana, Kazakhstan, 2Nazarbayev 
University, The Center for Life Sciences, Astana, Kazakhstan, 3Astana Medical University, Astana, 
Kazakhstan
objeCtives: This review aims to appraise the clinical and cost effectiveness of 
ivacaftor for oral administration for the treatment of cystic fibrosis (CF) in patients 
age six years and elder who have at least one G551D mutation in the CFTR (cystic 
fibrosis transmembrane conductance regulator) gene. Methods: A limited litera-
ture search was conducted of key resources, and titles and abstracts of the retrieved 
publications were reviewed. Full-text publications were evaluated for final article 
selection according to predetermined criteria (population, intervention, comparator, 
patients were found to be 100.1± 27.9 and 109 ± 15.0 .Among males, difference 
was observed in mean of HRQOL between ADR patients (99±27.92) and non ADR 
patients(107.16±14.08). Same difference were observed in mean of HRQOL among 
females which was102.18±28.68 in ADR Patients and113.69±15.95 in ADR absent 
patients. ConClusions: There is a need for a greater awareness among the health 
care professionals, regarding prevention or minimization of occurrence of ADRs by 
more frequent interventions by physicians, thus improving medication adherence 
which leads to maximization of HRQOL in HIV patients.
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SocIal aSPectS of HcV tReatMent In KazaKHStan
Almadiyeva A., Salpynov Z., Malykh D., Ivanov D., Sarkenova S.
Astana Medical University, Astana, Kazakhstan
objeCtives: Multiple treatments are available for chronic hepatitis C virus (HCV) 
infection. Ethical, clinical, economic, and social barriers often prevent these patients 
from receiving the effective antiviral treatments now available. These barriers to 
care have received little attention in the literature, and yet, knowledge of the ethical 
and social justice aspects of HCV treatment can enhance the quality of care. This 
study systematically reviewed evidence on the social and lifestyle determinants of 
achieving viral eradication with antiviral therapy. Methods: A search of Medline, 
Embase, and Cochrane databases (between 2004 and January 2014) was conducted 
for primary articles/conference abstracts examining social and lifestyle factors. 
Analyzed the main ethical arguments are often presented to restrict patients’ access 
to HCV treatment: the balance of risk/benefit, justice, compliance, cost-effectiveness 
and discrimination. Results: Clinical and individual level barriers to HCV treat-
ment are well evidenced. These include patient and provider concerns regarding 
co-morbidities, adherence, and side effect management. Social factors affecting 
treatment access are less well evidenced. In attempting to map these, key barri-
ers fall into the following domains: social stigma, housing, criminalisation, health 
care systems, and gender. Key facilitating factors to treatment access include: 
combination intervention approaches encompassing social as well as biomedi-
cal interventions and integrated delivery of multidisciplinary care. No trial evalu-
ated effectiveness of treatment on long-term clinical outcomes. ConClusions: 
Successful treatment of HCV infection has undeniable long-term benefits with 
respect to reducing morbidity and mortality. Perhaps the most challenging issue 
is not whether there will be medical tools to effectively manage and treat HCV 
infection, but rather whether the economic resources and societal commitment 
will be adequate to embark on an ambitious agenda to eliminate this global public 
health problem. Combination intervention approaches need to encompass systemic 
changes in policy and health care delivery. Future research needs to better delineate 
social factors affecting treatment access.
InfectIon – Health care use & Policy Studies
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an analySIS of tHe utIlIzatIon of cePHaloSPoRInS fRoM 2007 to 2011 
In guangdong PRoVInce of cHIna
Han S.1, Guan X.D.2, Wang T.1, Shi L.W.2, Li H.2, Xin X.1, Tian H.1, Li H.1
1Peking University, Beijing, China, 2International Research Center of Medicinal Administration, 
Peking University, Beijing, China
objeCtives: To analyze the relationship between the change of drug mix for 
Cephalosporins and their cost increases in order to provide a reference for future 
research and government policy making on cost of antacids and anti-ulcer medica-
tions. Methods: Build a foundation based on drug DDD unit, analyze the index 
analysis system of the influence of drug mix of Cephalosporins on drug cost on 
different levels. Results: The total procurement costs of Cephalosporins for 
Guangdong province and the purchases of DDD increased by 158% and 120% respec-
tively in 2007-2011. At the same time, the price level declined significantly, the price 
index calculated by Laspeyres index decreased by 12%. ConClusions: The amount 
of drug utilization is the most important factor that caused cost increase, the 
decline of price inhibits the Cephalosporins drug price growth to a certain extent. 
Technological innovation is the motivating factor to cause the Cephalosporins drug 
price to increase.  There is a link between the level index of administration route 
and the rationality of drug use. The competition among different manufacturers is 
an important factor that affects the total expenditure of Cephalosporins.
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tHe dIffeRenceS between InfectIouS & PaRaSItIc dRug aPPRoValS In 
jaPan and tHe uSa
Anderson R.1, Brooks-Rooney C.2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Singapore Pte Ltd., Singapore
objeCtives: Infectious and parasitic diseases encompass some of the most deadly 
diseases including HIV, the sixth leading cause of death worldwide. The aim of this 
study was to investigate the similarities and differences between the approval of 
new drugs for the treatment of infectious and parasitic diseases in Japan and the 
USA. Methods: Drugs approved from 2004 to 2013 were identified through publi-
cally available reports on the USA Food and Drug Administration (FDA) and the 
Japanese Pharmaceuticals and Medical Devices Agency (PMDA) websites. Relevant 
drugs were defined as related to the treatment of infectious and parasitic diseases, 
according to the World Health Organisation International Classification of Diseases 
Version 2010. Results: The FDA and PMDA approved similar numbers of drugs 
indicated for infectious and parasitic diseases at 31 and 33 drugs, respectively. 
Eight HIV drugs were approved by each organisation, of which 5 were approved 
by both; each of these drugs was approved by the PMDA in the same or following 
year after FDA approval. With the exception of HIV and malarial drugs, the indi-
cations of drugs varied considerably between the FDA and PMDA. Following HIV, 
the most common infectious and parasitic drug groups for the FDA were hepatitis 
(20%), mycoses (17%) and bacterial (13%) whereas the PMDA had high incidences of 
